Heat Biologics, Inc. (HTBX)
| Market Cap | 166.95M |
| Revenue (ttm) | 2.58M |
| Net Income (ttm) | -27.29M |
| Shares Out | 24.20M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $6.25 |
| Previous Close | $6.54 |
| Change ($) | -0.29 |
| Change (%) | -4.43% |
| Day's Open | 6.47 |
| Day's Range | 6.21 - 6.69 |
| Day's Volume | 400,440 |
| 52-Week Range | 3.71 - 30.10 |
InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.
DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...
DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, in...
DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, inc...
Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska. The post HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today ap...
Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.
Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangbusters Tod...
Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (niv...
Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune ...
Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination w...
Heat Biologics (HTBX) has announced details for a reverse stock split in order to keep shares of HTBX stock trading on the Nasdaq. The post Heat Biologics Reverse Stock Split: 10 Things for HTBX Stock I...
Heat Biologics boosts patents portfolio with gp96 combination award. Teleflex announces acquisition of hemostatic company Z-Medica.
Heat Biologics (HTBX) is in the news Thursday as HTBX stock takes a wild ride following an increasing focus on coronavirus stocks. The post Heat Biologics News: Why HTBX Stock Is On the Move Today appea...
A pre-print is sending the biotech's shares higher today.
Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.
Encouraging early results for the biotech's coronavirus vaccine have investors excited.
Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.
Heat Biologics and Vaxart could have a lot more room to run.
The biotech's COVID-19 vaccine candidate hit the mark in a preclinical study.
Heat Biologics Inc (NASDAQ: HTBX) shares are trading higher on Monday after the company announced the first patient has been treated in its first-in-human clinical trial of PTX-35.
The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.
As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...
About HTBX
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with a... [Read more...]
| Industry Biotechnology | IPO Date Jul 24, 2013 |
| CEO Jeffrey Wolf | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol HTBX |
Financial Performance
In 2020, Heat Biologics's revenue was $2.95 million, a decrease of -3.32% compared to the previous year's $3.05 million. Losses were -$26.05 million, 30.1% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Heat Biologics stock is "Strong Buy." The 12-month stock price forecast is 26.00, which is an increase of 316.00% from the latest price.